LLYPOINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyRunning, no new patients
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
Metastatic Castration-Resistant Prostate Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 455 (final count)
- Started
- Feb 25, 2021
- Main results expected
- Nov 1, 2023
- Fully finished
- Mar 2028
- Results posted
- Jan 13, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Randomization Phase: Radiographic Progression-Free Survival (rPFS)
Measured over: From the randomization date to the first documented progressive disease or death from any cause (up to 23 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04647526 · record last updated 2026-01-13 · checked 2026-11-09 15:36 UTC